Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9928605 | 0.81 | MAPT (0.47) | SMN1; SMN2ALDH1A1KMT2AKDM4EAGBL2 | |
| SCHEMBL30134211 | 0.81 | MAPT (0.47) | SMN1; SMN2ALDH1A1KMT2AKDM4EAGBL2 | |
| SCHEMBL12780298 | 0.80 | DPP4 (0.40) | AGBL2 | |
| SCHEMBL1499037 | 0.80 | GLA (0.49) | SMN1; SMN2ALDH1A1KMT2AKDM4EAGBL2 | |
| SCHEMBL6033804 | 0.78 | KMT2A (0.53) | SMN1; SMN2ALDH1A1KMT2AKDM4EAGBL2 | |
| SCHEMBL22208505 | 0.77 | MAPK1 (0.47) | SMN1; SMN2ALDH1A1KMT2AKDM4EAGBL2 | |
| SCHEMBL18412886 | 0.77 | PKM (0.52) | SMN1; SMN2ALDH1A1KMT2AKDM4EAGBL2 | |
| SCHEMBL12780507 | 0.77 | BACE1 (0.36) | SMN1; SMN2LMNA | |
| SCHEMBL22060645 | 0.75 | HCAR2 (0.41) | ALDH1A1KMT2AKDM4EMAPK1LMNA | |
| Formic Acid SCHEMBL2591954 | 0.73 | ALDH1A1 (0.50) | SMN1; SMN2ALDH1A1KMT2AKDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10640506-B2 | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190135813-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINES DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2019-05-09 | — | — | US | disclosed |
| US-9249145-B2 | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150087632-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINES DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2015-03-26 | — | — | US | disclosed |
| US-8933085-B2 | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2015-01-13 | — | — | US | disclosed |
| US-20120149681-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2012-06-14 | — | — | US | disclosed |
| US-20110059951-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059951-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | SMN1; SMN2 4287/4885ALDH1A1 3201/4885KMT2A 1472/4885 |
| US-10640506-B2 | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors | JAK2, JAK1, JAK3 | SMN1; SMN2 4536/4885ALDH1A1 3935/4885KMT2A 1287/4885 |
| US-20120149681-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | SMN1; SMN2 4468/4885ALDH1A1 3852/4885KMT2A 1210/4885 |
| US-20150087632-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINES DERIVATIVES AS JAK INHIBITORS | JAK2, JAK1, JAK3 | SMN1; SMN2 4536/4885ALDH1A1 3935/4885KMT2A 1287/4885 |
| US-20190135813-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINES DERIVATIVES AS JAK INHIBITORS | JAK2, JAK1, JAK3 | SMN1; SMN2 4536/4885ALDH1A1 3935/4885KMT2A 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.